2024

FileAction
PCMA comments on NBPP 2025 Proposed Rule - January 8 2024.pdfDownload
PCMA comments on CMS 4205P CY2025 Part D rule - January 4 2024.pdfDownload
PCMA comments on Info Blocking Disincentives proposed rule - January 2 2024.pdfDownload

2023

File
PCMA comments to EBSA OTC RFI - December 4 2023.pdf
PCMA comments to Medicaid RFI on MHPAEA - December 4 2023.pdf
PCMA response to MTF RFI - November 13 2023.pdf
PCMA final comments for 504 proposed rule - November 13 2023.pdf
PCMA comment letter on MHPAEA NPRM - October 17 2023.pdf
PCMA comments on Medicare Prescription Payment Plan Guidance - September 20, 2023.pdf
2024 Propsed PFS PCMA Comments - September 11 2023.pdf
PCMA comments on CMS-10849 negotiation offer ICR - August 24 2023.pdf
PCMA comments on CY2025 proposed EOB model - August 7 2023.pdf
PCMA comments on MDP – August 7, 2023.pdf
PCMA comments re CMS 10847 - ICR 30 day comments - July 31 2023.pdf
PCMA comments on MDRP - July 25 2023.pdf
PCMA comments related to ONC HTI-1 proposed rule - June 20 2023.pdf
PCMA comments on CMS-10849 negotiation offer ICR - June 20 2023.pdf
PCMA comments on CMS-10849 negotiation offer ICR - June 20 2023.pdf
PCMA comments on HIPAA Privacy Rule To Support Reproductive Health Care Privacy - June 16 2023.pdf
PCMA comments on MDP initial guidance - June 12 2023.pdf
PCMA comments on CY 2025 benefit design - June 5 2023.pdf
PCMA comments on CMS-10788 RxDC PRA - May 25 2023.pdf
PCMA comments on CMS-10844 Small Biotech Exception - 30 day - May 24 2023.pdf
PCMA comments on CMS-10847 negotiation elements - May 22 2023.pdf
PCMA comments on IRA IPAY 2026 Guidance - April 14, 2023.pdf
PCMA comments on CMS-10846 MDP agreement - April 10 2023.pdf
PCMA comments on Coverage of Certain Preventive Services - April 3 2023.pdf
PCMA comments on CMS-10844 Small Biotech Exception - March 27 2023.pdf
Advancing Interoperability and Improving Prior Authorization - PCMA Comments - March 13 2023.pdf
PCMA comments on Medicare Part D Inflation Rebate - March 10, 2023.pdf
PCMA comments on CY 2024 Advance Notice - March 6 2023.pdf
PCMA comments on CMS-4201 2024 Part C D rule - February 13 2023.pdf
PCMA comments on Part 2 proposed rule - January 31 2023.pdf
PCMA Comments in response to USPTO RFI - January 31 2023.pdf
PCMA comments on EHB RFI - January 30 2023.pdf
PCMA comment on 2024 NBPP Proposed Rule - January 30 2023.pdf
PCMA comments to MedCAC re CED - January 13, 2023.pdf
PCMA comments on Draft 2024 Letter to Issuers in the FFEs - January 12, 2023.pdf
PCMA comments on CMS Plan Benefit Package (PBP) and Formulary CY 2024 - January 9 2023.pdf
PCMA comments on F6 Retail Pharmacy Standards and Subrogation Standard - January 9 2023.pdf

2022

File
PCMA Comments in Response to AEOB GFE RFI - November 14 2022.pdf
PCMA Comments on CMS Post-COVID RFI - Make Your Voice Heard - November 3, 2022.pdf
PCMA Comments on 1557 Proposed Rule - October 3 2022.pdf
PCMA Comments on AHRQ CED - September 28, 2022.pdf
PCMA Comments on CY2023 Physician Fee Schedule - September 6 2022.pdf
PCMA Comments on HHS Primary Care RFI - August 1, 2022.pdf
PCMA comments on Section 204 - RxDC - CMS-10788 - July 28, 2022.pdf
PCMA comments on OA REMS - June 21 2022.pdf
PCMA comments on HIPAA HITECH RFI - June 6 2022.pdf
PCMA comments on DHS Public Charge - April 25 2022.pdf
PCMA response to ONC RFI on e-PA - March 24 2022.pdf
PCMA Comments on CY2023 Policy and Technical Changes (CMS-4192-P) - March 7 2022.pdf
PCMA comments on CY 2023 Advance Notice - March 4 2022.pdf
PCMA comments on CMS-10141 CY2023 Model EOBs February 18 2022.pdf
PCMA comments on proposed NCD for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease - February 10, 2022.pdf
PCMA comments on 2023 Letter to Issuers in the Federally-facilitated Exchanges - January 27, 2022.pdf
PCMA comments on CY2023 NBPP - January 27 2022.pdf
PCMA comments on Prescription Drug and Healthcare Spending - January 24 2022.pdf
PCMA comments on DEA Transfer of Electronic Prescriptions - January 18 2022.pdf
PCMA comments on Regulation of Telepharmacy Practice - January 18 2022.pdf
PCMA comments on CMS vaccination mandate IFR - January 4 2022.pdf
PCMA Comments on CMS OTP Payment Freeze for Methadone - January 3 2022.pdf

2021

File
PCMA comments on RFI Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs - July 23 2021.pdf
PCMA Comments on Medicaid VBP - June 28 2021.pdf
PCMA Letter to Tri-Depts re PBM provisions May 14 2021.pdf
PCMA comments on CMS MCIT Delay - April 15 2021.pdf
PCMA comment letter on DEA Registration Number Surrendered Memos - April 13, 2021.pdf
PCMA March-In Rights Comment Letter - April 2 2021.pdf
PCMA comments on Biosimilars Citizen Petition - March 19 2021.pdf
PCMA MPF CMS Response - February 4, 2021.pdf
PCMA Comments on Information Collection Request - March 1 2021.pdf
PCMA comments on MFN - CMS-5528-IFC - January 26 2021.pdf
PCMA comments on ICR CMS-10756 - January 8 2021.pdf
PCMA comments on CMS-9123 January 4, 2021.pdf
PCMA comments on CMS-9912-IFC January 1, 2021.pdf
PCMA comments on HHS SUNSET proposed rule - Medicare - January 1, 2021.pdf

2020

File
PCMA comments on 2021 Physican Fee Schedule - October 2, 2020.pdf
PCMA comments on NBPP 2022 proposed rule December 28, 2020.pdf
PCMA comments on COVID regulatory relief RFI December 26, 2020.pdf
PCMA comments on HHS SUNSET proposed rule - December 4, 2020.pdf
PCMA Questions for FDA and CMS Regarding Personal Importation - December 3, 2020.pdf
PCMA comments on CY 2022 Advance Notice Part 2 - November 30, 2020.pdf
PCMA comments on CMS Medicare Coverage of Innovative Technology - November 2, 2020.pdf
PCMA comments on 30-day notice - CMS 10725 - October 13, 2020.pdf
PCMA comments on EPCS RFI - October 2, 2020.pdf
PCMA comments on Proposed Rebate Rule - August 3, 2020.pdf
PCMA Good Guidance Practices Comments - September 16 2020.pdf
PCMA comments on CMS VBP and Medicaid Drug Rebate Proposed - July 17, 2020.pdf
PCMA Comments on CMS-5531-IFC - July 1, 2020.pdf
PCMA comments on CMS notice - Agency Information Collection Activities Submission for OMB Review - Document Number 10717- June 30, 2020.pdf
PCMA comments on Policy and Regulatory Revisions in Response to the COVID–19 Public Health Emergency - CMS-1744-IFC.pdf
PCMA 2021 NPRM Comments - April 6, 2020.pdf
PCMA Comments on CMS10725 - Pharmacy Benefit Manager Transparency for QHPs- March 30, 2020.pdf
PCMA Comments on the 2021 Advance Notice Part II - March 6, 2020.pdf
PCMA Comments on NBPP 2021 - March 2, 2020.pdf
PCMA Comments on Importation of Certain FDA-Approved Human Prescription Drugs - March 2, 2020.pdf
PCMA Comments on FDA Draft Guidance - February 20, 2020.pdf
PCMA Comments on Transparency in Coverage Proposed Rule - January 29, 2020.pdf

2019

File
PCMA comments on AKS proposed rule - December 20, 2019.pdf
PCMA Comments on PFS 2020 Proposed Rule re OTP - September 25, 2019.pdf
PCMA Comments on RFI - Ensuring Patient Access and Effective Drug Enforcement - August 26, 2019.pdf
PCMA Comments on ePA - August 15, 2019.pdf
PCMA 1557 Comment Letter - August 13, 2019.pdf
PCMA Comments on Reducing Administrative Burden RFI - August 12, 2019.pdf
PCMA Comments on Safe Harbor Proposed Regulations - April 8, 2019.pdf
PCMA Comments on 2020 Advance Notice and Draft 2020 Call Letter - February 28, 2019.pdf
PCMA Comments on NBPP 2020 Proposed Rule - February 15, 2019.pdf
PCMA Comments on Medicaid Managed Care NPRM - January 11, 2019.pdf
PCMA Comments on Modernizing Part D and MA to Lower Drug Prices and Reduce Out of Pocket Costs - January 24, 2019.pdf

2018

File
PCMA Comments on Part D 2020 NPRM – December 21, 2018.pdf
PCMA comments on Medicare and Medicaid Programs - Regulation To Require Drug Pricing Transparency - December 6, 2018.pdf
PCMA Comments on ANPRM - International Pricing Index Model for Part B Drugs - December 6, 2018.pdf
Final PCMA Comments on Section 1332 Waiver Guidance - November 27, 2018.pdf
PCMA Comment to FDA on Citizen Petition Reforms FINAL 12-03-18.pdf
PCMA Comments on Public Charge NPRM - November 28, 2018.pdf
PCMA Comments on the Changes to the Medicare Claims and Medicare Prescription Drug Coverage Determination Appeals Procedures - November 28, 2018.pdf
PCMA Comments on HHS OIG RFI on AKS Safe Harbors - October 23, 2018.pdf
PCMA Comments on CAP RFI - September 21, 2018.pdf
PCMA comments on proposed Medicare DIR Reporting Requirements for 2017 - May 4, 2018.pdf
PCMA Comments on Short-Term Limited Duration Insurance NPRM - April 23, 2018.pdf
PCMA Comments on Protecting Statutory Conscience Rights in Health Care NPRM - March 27 2018.pdf
PCMA Comments on Advance Notice and 2019 Call Letter - March 2, 2018.pdf
PCMA Comments on ASPE RFI - January 25, 2018.pdf
PCMA comments on the 2019 Part D NPRM and RFI - January 16, 2018.pdf

2017

File
PCMA Comments Religious and Moral Accommodation IFRs - December 5, 2017.pdf
PCMA Comments Religious and Moral Accommodation IFRs - December 5, 2017.pdf
PCMA Comments 2019 NBPP NPRM - November 17, 2017.pdf
PCMA CMMI RFI Comments - November 20, 2017.pdf
PCMA comments on USP DC - October 30, 2017.pdf
PCMA Comments on HHS Strategic Plan - October 25, 2017.pdf
PCMA Comments MA 1115 Waiver Request 10_20_2017.pdf
PCMA Comment Letter - Part B NPRM Biosimilars Policy - September 11, 2017.pdf
PCMA Letter to CMS re Opioid RFI ESRD Proposed Rule - August 28, 2017.pdf
PCMA Comments on Patient Protection and Affordable Care Act RFI - July 12, 2017
PCMA Comment Letter on CMS Opioids RFI - June 13, 2017
PCMA comments on proposed Medicare DIR Reporting Requirements for 2016 - June 2, 2017
PCMA MPF Price Accuracy Letter - May 22, 2017
PCMA Comments on 2017 Transformation Ideas - April 24, 2017
PCMA Comments on Advance Notice and 2018 Call Letter - March 3, 2017
PCMA Comments on Market Stabilization Proposed Rule - March 3, 2017
PCMA Letter to Delay Medicaid Managed Care Rule - January 30, 2017

2021

File
PCMA comments on RFI Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs – July 23 2021.pdf
PCMA Comments on Medicaid VBP – June 28 2021.pdf
PCMA Letter to Tri-Depts re PBM provisions May 14 2021.pdf
PCMA comments on CMS MCIT Delay – April 15 2021.pdf
PCMA comment letter on DEA Registration Number Surrendered Memos – April 13, 2021.pdf
PCMA March-In Rights Comment Letter – April 2 2021.pdf
PCMA comments on Biosimilars Citizen Petition – March 19 2021.pdf
PCMA MPF CMS Response – February 4, 2021.pdf
PCMA Comments on Information Collection Request – March 1 2021.pdf
PCMA comments on MFN – CMS-5528-IFC – January 26 2021.pdf
PCMA comments on ICR CMS-10756 – January 8 2021.pdf
PCMA comments on CMS-9123 January 4, 2021.pdf
PCMA comments on CMS-9912-IFC January 1, 2021.pdf
PCMA comments on HHS SUNSET proposed rule – Medicare – January 1, 2021.pdf

2020

File
PCMA comments on 2021 Physican Fee Schedule – October 2, 2020.pdf
PCMA comments on NBPP 2022 proposed rule December 28, 2020.pdf
PCMA comments on COVID regulatory relief RFI December 26, 2020.pdf
PCMA comments on HHS SUNSET proposed rule – December 4, 2020.pdf
PCMA Questions for FDA and CMS Regarding Personal Importation – December 3, 2020.pdf
PCMA comments on CY 2022 Advance Notice Part 2 – November 30, 2020.pdf
PCMA comments on CMS Medicare Coverage of Innovative Technology – November 2, 2020.pdf
PCMA comments on 30-day notice – CMS 10725 – October 13, 2020.pdf
PCMA comments on EPCS RFI – October 2, 2020.pdf
PCMA comments on Proposed Rebate Rule – August 3, 2020.pdf
PCMA Good Guidance Practices Comments – September 16 2020.pdf
PCMA comments on CMS VBP and Medicaid Drug Rebate Proposed – July 17, 2020.pdf
PCMA Comments on CMS-5531-IFC – July 1, 2020.pdf
PCMA comments on CMS notice – Agency Information Collection Activities Submission for OMB Review – Document Number 10717- June 30, 2020.pdf
PCMA comments on Policy and Regulatory Revisions in Response to the COVID–19 Public Health Emergency – CMS-1744-IFC.pdf
PCMA 2021 NPRM Comments – April 6, 2020.pdf
PCMA Comments on CMS10725 – Pharmacy Benefit Manager Transparency for QHPs- March 30, 2020.pdf
PCMA Comments on the 2021 Advance Notice Part II – March 6, 2020.pdf
PCMA Comments on NBPP 2021 – March 2, 2020.pdf
PCMA Comments on Importation of Certain FDA-Approved Human Prescription Drugs – March 2, 2020.pdf
PCMA Comments on FDA Draft Guidance – February 20, 2020.pdf
PCMA Comments on Transparency in Coverage Proposed Rule – January 29, 2020.pdf

2019

File
PCMA comments on AKS proposed rule – December 20, 2019.pdf
PCMA Comments on PFS 2020 Proposed Rule re OTP – September 25, 2019.pdf
PCMA Comments on RFI – Ensuring Patient Access and Effective Drug Enforcement – August 26, 2019.pdf
PCMA Comments on ePA – August 15, 2019.pdf
PCMA 1557 Comment Letter – August 13, 2019.pdf
PCMA Comments on Reducing Administrative Burden RFI – August 12, 2019.pdf
PCMA Comments on Safe Harbor Proposed Regulations – April 8, 2019.pdf
PCMA Comments on 2020 Advance Notice and Draft 2020 Call Letter – February 28, 2019.pdf
PCMA Comments on NBPP 2020 Proposed Rule – February 15, 2019.pdf
PCMA Comments on Medicaid Managed Care NPRM – January 11, 2019.pdf
PCMA Comments on Modernizing Part D and MA to Lower Drug Prices and Reduce Out of Pocket Costs – January 24, 2019.pdf

2018

File
PCMA Comments on Part D 2020 NPRM – December 21, 2018.pdf
PCMA comments on Medicare and Medicaid Programs – Regulation To Require Drug Pricing Transparency – December 6, 2018.pdf
PCMA Comments on ANPRM – International Pricing Index Model for Part B Drugs – December 6, 2018.pdf
Final PCMA Comments on Section 1332 Waiver Guidance – November 27, 2018.pdf
PCMA Comment to FDA on Citizen Petition Reforms FINAL 12-03-18.pdf
PCMA Comments on Public Charge NPRM – November 28, 2018.pdf
PCMA Comments on the Changes to the Medicare Claims and Medicare Prescription Drug Coverage Determination Appeals Procedures – November 28, 2018.pdf
PCMA Comments on HHS OIG RFI on AKS Safe Harbors – October 23, 2018.pdf
PCMA Comments on CAP RFI – September 21, 2018.pdf
PCMA comments on proposed Medicare DIR Reporting Requirements for 2017 – May 4, 2018.pdf
PCMA Comments on Short-Term Limited Duration Insurance NPRM – April 23, 2018.pdf
PCMA Comments on Protecting Statutory Conscience Rights in Health Care NPRM – March 27 2018.pdf
PCMA Comments on Advance Notice and 2019 Call Letter – March 2, 2018.pdf
PCMA Comments on ASPE RFI – January 25, 2018.pdf
PCMA comments on the 2019 Part D NPRM and RFI – January 16, 2018.pdf

2017

File
PCMA Comments Religious and Moral Accommodation IFRs – December 5, 2017.pdf
PCMA Comments Religious and Moral Accommodation IFRs – December 5, 2017.pdf
PCMA Comments 2019 NBPP NPRM – November 17, 2017.pdf
PCMA CMMI RFI Comments – November 20, 2017.pdf
PCMA comments on USP DC – October 30, 2017.pdf
PCMA Comments on HHS Strategic Plan – October 25, 2017.pdf
PCMA Comments MA 1115 Waiver Request 10_20_2017.pdf
PCMA Comment Letter – Part B NPRM Biosimilars Policy – September 11, 2017.pdf
PCMA Letter to CMS re Opioid RFI ESRD Proposed Rule – August 28, 2017.pdf
PCMA Comments on Patient Protection and Affordable Care Act RFI – July 12, 2017
PCMA Comment Letter on CMS Opioids RFI – June 13, 2017
PCMA comments on proposed Medicare DIR Reporting Requirements for 2016 – June 2, 2017
PCMA MPF Price Accuracy Letter – May 22, 2017
PCMA Comments on 2017 Transformation Ideas – April 24, 2017
PCMA Comments on Advance Notice and 2018 Call Letter – March 3, 2017
PCMA Comments on Market Stabilization Proposed Rule – March 3, 2017
PCMA Letter to Delay Medicaid Managed Care Rule – January 30, 2017